{"id":"W2265121903","doi":"10.1007/s10637-016-0324-0","title":"A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Health Sciences Centre; Ontario Clinical Oncology Group; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Hamilton Health Sciences","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Nausea; Internal medicine; Progressive disease; Melanoma; Adverse effect; Gastroenterology; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Oncology; Toxicity; Chemotherapy; Surgery; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001543141,0.0002025806,0.0002364322,0.00008804083,0.00005049711,0.000009888512,0.0001612584,0.00005730166,0.00004107812],"category_scores_gemma":[0.00009444702,0.000120494,0.00003153512,0.0001693034,0.00008918297,0.00001955186,0.00006872157,0.00004792554,0.000004450547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002634542,"about_ca_system_score_gemma":0.0004553775,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001625737,"about_ca_topic_score_gemma":0.0006067439,"domain_scores_codex":[0.9985287,0.0001474545,0.0003957997,0.0003990553,0.0003053622,0.0002236234],"domain_scores_gemma":[0.9991715,0.00002345016,0.0001776555,0.0002743887,0.0001410995,0.0002119312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0111149,0.02980305,0.2779865,0.0001917553,0.0006923965,0.0001183389,0.01117983,0.00006735307,0.5877476,0.0009891817,0.00509287,0.07501623],"study_design_scores_gemma":[0.1635797,0.202925,0.09460555,0.00127203,0.0004827799,0.00004818035,0.0016241,0.0001669687,0.5215206,0.002184005,0.009402692,0.002188426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989253,0.00004912476,0.00004371686,0.00008919318,0.00007911432,0.0006686146,0.00008864832,0.00001102439,0.00004530417],"genre_scores_gemma":[0.9982793,0.000005588699,0.0008656528,0.00007953108,0.0000747721,0.00005105305,0.0003071605,0.00002227888,0.00031463],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.183381,"threshold_uncertainty_score":0.4913602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02402729017134401,"score_gpt":0.2711577410912109,"score_spread":0.2471304509198669,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}